Stock Locations

New Jersey, USA
Czech Republic, EU
Mumbai, India

* Stock subject to availability.

Documentation

Download MSDS

Download Sample COA

Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.

2715120- 86-6Upadacitinib Bisacyl Impurity

● In Stock

Catalogue No.:	VE0027853
CAS No.:	2715120- 86-6
Mol. Formula:	C20H21F6N7O2
Mol. Weight:	505.42 g/mol

Request a quote

Add to RFQ list

Additional information on CAS 2715120- 86-6

Parent drug

Upadacitinib

IUPAC Name

8-((3R,4S)-4-ethyl-1-((2,2,2-trifluoroethyl)carbamoyl) pyrrolidin-3-yl)-N-(2,2,2- trifluoroethyl)-3H-imidazo[1,2-a] pyrrolo[2,3-e]pyrazine-3-carboxamide

Pharmacopeial Synonyms

N/A

Synonyms

N/A

Smiles

O=C(N1C=CC2=C1N=CC3=NC=C([C@H]4CN(C(NCC(F)(F)F)=O)C[C@H]4CC)N32)NCC(F)(F)F

InChI

InChI=1S/C20H21F6N7O2/c1-2-11-7-31(17(34)29-9-19(21,22)23)8-12(11)14-5-27-15-6-28-16-13(33(14)15)3-4-32(16)18(35)30-10-20(24,25)26/h3-6,11-12H,2,7-10H2,1H3,(H,29,34)(H,30,35)/t11-,12+/m1/s1

Description

Upadacitinib Bisacyl Impurity (CAS 2715120-86-6) is a process-related degradant detected during upadacitinib synthesis and stability testing. Analytical characterization by LC-MS, HPLC and NMR confirms the bisacyl structural motif and mass shift indicative of acylation of the parent scaffold. Left uncontrolled, this impurity can affect API purity and stability, so validated quantitation methods with MS confirmation and forced-degradation studies are recommended for reliable impurity profiling. Control measures typically target acylation step optimization, purification parameter adjustment and specification setting in line with ICH Q3A/B thresholds, with reporting of retention time, exact mass and fragmentation pattern.